These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Roche and Merck begin expanded access programs for protease inhibitor drugs.
    Author: Baker R.
    Journal: BETA; 1995 Sep; ():4. PubMed ID: 11362890.
    Abstract:
    Hoffman LaRoche and Merck have agreed to expand enrollment in their Invirase and Crixivan programs if the drug availability increases. The Roche program offers Invirase to HIV-positive individuals with CD4 cell counts under 300. The Merck program provides Crixivan to people with AIDS who have fifty or fewer CD4 cells. Originally, both programs were open only to individuals who were intolerant to, or had failed, standard treatments for HIV infection.
    [Abstract] [Full Text] [Related] [New Search]